Evidence on the identity of the CXCR2 antagonist AZD-5069

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 1, 2013, Pages 113-117

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

AZD 5069; Chemokine; COPD; CXCR2; IL 8; Inflammation

Indexed keywords

ARD 8309; ASCORBIC ACID; AZD 5069; AZD 8309; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DANIRIXIN; ELUBRIXIN; INTERLEUKIN 8; IODINE 125; LADARIXIN; NAVARIXIN; PYRIMIDINE DERIVATIVE; REPARIXIN; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; BRONCHIECTASIS; BULLOUS PEMPHIGOID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; ENTERITIS; GRAFT REJECTION; HUMAN; IRRITABLE COLON; NEOPLASM; OSTEOARTHRITIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ANIMALS; CRYSTALLIZATION; HUMANS; INFLAMMATION; PATENTS AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-8B;

EID: 84871500153     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.725724     Document Type: Article

References (22)

1. Murphy PM, Charo IF, Hills R, et al. Chemokine receptors, introductory chapter. Last Last modified on 13/10/ 2009. IUPHAR database (IUPHAR-DB) Available from: http://www.iuphar-db. org/DATABASE/FamilyIntroduction Forward?familyId=14 [Accessed 1 August 2012]
2. Busch-Peterson J, Wang Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin Ther Patents 2008;18(6):629-37 (Pubitemid 351954357)
3. Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Patents 2009;19(2):199-221
4. Chung KF. Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005;4(6):619-25 (Pubitemid 41722372)
5. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):478-85 (Pubitemid 351669174)
6. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998; 273(17):10095-8 (Pubitemid 28227606)
7. SmithKline Beecham Corp. IL-8 Receptor Antagonists. WO1996025157; 1996
8. Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121(1):55-68
9. Virtala R, Ekman AK, Jansson L, et al. Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor. Clin Exp Allergy 2012;42(4):590-6
10. Lazaar AL, Sweeney LE, MacDonald AJ, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72(2):282-93
11. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebocontrolled clinical trial. Clin Exp Allergy 2012;42(7):1097-103
12. Nicholls DJ, Tomkinson NP, Wiley KE, et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 2008;74(5):1193-202
13. Salchow K, BondME, Evans SC, et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 2010;159(7):1429-39
14. de Kruijf P, Lim HD, Roumen L, et al. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 2011; 80(6):1108-18
15. Bertini R, Barcelos LS, Beccari AR, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/ CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 2012; 165(2):436-54
16. NCT01233232 A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS). Available from: http://www.clinicaltrial.gov/ct2/ show/NCT01233232
17. NCT01255592 Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (STRATUS). Available from: http://clinicaltrials.gov/ct2/show/ NCT01255592
18. AstraZeneca AB, AstraZeneca UK Ltd. New crystalline forms of N-[2-[[(2,3- difluoropheny)methyl)thio]-6-{[(1R,2S)- 2,3-dihydroxy-1-methylpropyl]oxy}-4- pyrimidinyl]-1-azetidinesulfonamide. WO2012007748; 2012
19. AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidine sulphonamide derivatives as chemokine receptor modulators. WO2006024823; 2006
20. Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008;18(2):798-803
21. AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidyl sulphone amide derivatives as chemokine receptor modulators. WO2004011443; 2004
22. AstraZeneca AB, AstraZeneca UK Ltd. Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases. WO2010007427; 2010